marimastat has been researched along with Cancer of Liver in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bian, H; Chen, ZN; Feng, F; Nan, G; Sun, XX; Wang, B; Wang, Y; Wei, D; Yang, XM; Yuan, L | 1 |
| King, J; Morris, DL; North, H | 1 |
| Ichikawa, Y; Ishikawa, T; Shimada, H; Tanaka, K; Togo, S | 1 |
| Hori, T; Ido, A; Tsubouchi, H | 1 |
| Balabaud, C; Bisson, C; Desmoulière, A; Monvoisin, A; Rosenbaum, J; Si-Tayeb, K | 1 |
2 review(s) available for marimastat and Cancer of Liver
| Article | Year |
|---|---|
[Extracellular matrix degradation enzymes: important factors in liver metastasis of colorectal cancer and good targets for anticancer metastatic therapy].
Topics: Colorectal Neoplasms; Enzyme Inhibitors; Extracellular Matrix; Humans; Hydroxamic Acids; Liver Neoplasms; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasm Invasiveness; Neovascularization, Pathologic; Plasminogen Activators | 2001 |
[Tumor dormancy therapy for hepatocellular carcinoma].
Topics: Angiostatins; Antibodies; Antineoplastic Agents; Carcinoma, Hepatocellular; Collagen; Endostatins; Endothelial Growth Factors; Hepatocyte Growth Factor; Humans; Hydroxamic Acids; Liver Neoplasms; Lymphokines; Matrix Metalloproteinase Inhibitors; Mitogens; Peptide Fragments; Plasminogen; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
1 trial(s) available for marimastat and Cancer of Liver
| Article | Year |
|---|---|
Effect of marimastat on serum tumour markers in patients with colorectal cancer.
Topics: Adult; Aged; Carcinoembryonic Antigen; Colorectal Neoplasms; Enzyme Inhibitors; Female; Humans; Hydroxamic Acids; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2000 |
2 other study(ies) available for marimastat and Cancer of Liver
| Article | Year |
|---|---|
A chimeric antibody targeting CD147 inhibits hepatocellular carcinoma cell motility via FAK-PI3K-Akt-Girdin signaling pathway.
Topics: Animals; Antibodies; Antibody-Dependent Cell Cytotoxicity; Basigin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; CHO Cells; Cricetulus; Female; Focal Adhesion Kinase 1; Hep G2 Cells; Humans; Hydroxamic Acids; Immunoglobulin G; Immunoglobulin kappa-Chains; Liver Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred BALB C; Microfilament Proteins; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pseudopodia; Recombinant Fusion Proteins; Signal Transduction; Single-Chain Antibodies; Stress Fibers; Vesicular Transport Proteins | 2015 |
Involvement of matrix metalloproteinase type-3 in hepatocyte growth factor-induced invasion of human hepatocellular carcinoma cells.
Topics: Blotting, Northern; Blotting, Western; Carcinoma, Hepatocellular; Collagen; DNA Primers; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Hepatocyte Growth Factor; Humans; Hydroxamic Acids; Laminin; Liver Neoplasms; Matrix Metalloproteinase 3; Matrix Metalloproteinase Inhibitors; Metalloendopeptidases; Proteoglycans; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured | 2002 |